Neurosense Therapeutics Stock Buy Hold or Sell Recommendation
| NRSN Stock | USD 1.09 0.03 2.68% |
Given the investment horizon of 90 days and your way above-average risk tolerance, our recommendation regarding Neurosense Therapeutics is 'Strong Sell'. The recommendation algorithm takes into account all of Neurosense Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Neurosense Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide. In addition, we conduct extensive research on individual companies such as Neurosense and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Neurosense |
Execute Neurosense Therapeutics Buy or Sell Advice
The Neurosense recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Neurosense Therapeutics. Macroaxis does not own or have any residual interests in Neurosense Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Neurosense Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Abnormally volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Neurosense Therapeutics Trading Alerts and Improvement Suggestions
| Neurosense Therapeutics had very high historical volatility over the last 90 days | |
| Neurosense Therapeutics has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (11.28 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Neurosense Therapeutics currently holds about 10.37 M in cash with (8.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Roughly 31.0% of the company outstanding shares are owned by corporate insiders |
Neurosense Therapeutics Returns Distribution Density
The distribution of Neurosense Therapeutics' historical returns is an attempt to chart the uncertainty of Neurosense Therapeutics' future price movements. The chart of the probability distribution of Neurosense Therapeutics daily returns describes the distribution of returns around its average expected value. We use Neurosense Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Neurosense Therapeutics returns is essential to provide solid investment advice for Neurosense Therapeutics.
| Mean Return | 0.14 | Value At Risk | -7.53 | Potential Upside | 8.74 | Standard Deviation | 5.70 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Neurosense Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Neurosense Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Neurosense Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Neurosense Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Neurosense stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.13 | |
β | Beta against Dow Jones | 0.16 | |
σ | Overall volatility | 5.70 | |
Ir | Information ratio | 0.02 |
Neurosense Therapeutics Volatility Alert
Neurosense Therapeutics exhibits above-average semi-deviation for your current time horizon. Neurosense Therapeutics is a potential penny stock. Although Neurosense Therapeutics may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Neurosense Therapeutics. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Neurosense instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Neurosense Therapeutics Fundamentals Vs Peers
Comparing Neurosense Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Neurosense Therapeutics' direct or indirect competition across all of the common fundamentals between Neurosense Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Neurosense Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Neurosense Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Neurosense Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Neurosense Therapeutics to competition |
| Fundamentals | Neurosense Therapeutics | Peer Average |
| Return On Equity | -4.95 | -0.31 |
| Return On Asset | -1.51 | -0.14 |
| Current Valuation | 24.99 M | 16.62 B |
| Shares Outstanding | 23.23 M | 571.82 M |
| Shares Owned By Insiders | 31.37 % | 10.09 % |
| Shares Owned By Institutions | 0.97 % | 39.21 % |
| Number Of Shares Shorted | 200.1 K | 4.71 M |
| Price To Book | 4.15 X | 9.51 X |
| EBITDA | (10.63 M) | 3.9 B |
| Net Income | (11.28 M) | 570.98 M |
| Cash And Equivalents | 10.37 M | 2.7 B |
| Cash Per Share | 0.89 X | 5.01 X |
| Total Debt | 142 K | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 15.09 X | 2.16 X |
| Book Value Per Share | (0.11) X | 1.93 K |
| Cash Flow From Operations | (8.45 M) | 971.22 M |
| Short Ratio | 2.01 X | 4.00 X |
| Earnings Per Share | (0.76) X | 3.12 X |
| Target Price | 7.5 | |
| Number Of Employees | 18 | 18.84 K |
| Beta | 1.57 | -0.15 |
| Market Capitalization | 25.32 M | 19.03 B |
| Total Asset | 3.18 M | 29.47 B |
| Retained Earnings | (32.07 M) | 9.33 B |
| Working Capital | (543 K) | 1.48 B |
| Net Asset | 3.18 M |
Neurosense Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Neurosense . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Neurosense Therapeutics Buy or Sell Advice
When is the right time to buy or sell Neurosense Therapeutics? Buying financial instruments such as Neurosense Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Neurosense Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Equity ETFs Thematic Idea Now
Broad Equity ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Equity ETFs theme has 481 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Equity ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Neurosense Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.